Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

JUŘICA Jan GONĚC Roman BÁRTOVÁ Adéla GREGOROVÁ Jana

Year of publication 2022
Type Article in Periodical
Magazine / Source European Pharmaceutical Journal
MU Faculty or unit

Faculty of Medicine

Citation
Web https://sciendo.com/es/article/10.2478/afpuc-2022-0006
Doi http://dx.doi.org/10.2478/afpuc-2022-0006
Keywords Immune checkpoint inhibitors; immunotherapy; adverse effect; autoimmunity
Description Autoimmune adverse effects of immune checkpoint inhibitors (ICIs) are rare but may be life-threatening. We performed a retrospective analysis of the immune-related adverse effects (irAEs) of ICIs in the Masaryk Memorial Cancer Institute (MMCI) from 2011 to 2021. The ICIs were administered to 648 patients. Severe irAEs were pronounced in 83 patients (12.8%). Further, we report a case of severe irAE after treatment with ipilimumab and nivolumab. Prednisone, mesalazine, octreotide, infliximab, vedolizumab, and mycophenolate mofetil were used to manage G4 colitis, with partial response. Early diagnosis and appropriate management of irAE are essential in the perspective of further oncological treatment.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.